These were some of the questions addressed by the University of Toronto’s Geoffrey Hinton – a University Professor emeritus ...

The recommendation for Enflonsia is indicated for respiratory syncytial virus prevention in infants under eight months of age, expanding protection options ahead of the 2025–2026 season.

Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other products. Read why MRK is a Buy.

Stay with Moneycontrol to get real time updates on US MARKET share price, top gainers, top losers and market insights.

Enflonsia is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody that is designed to provide durable protection through 5 months.

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

On April 8, when stocks were on the verge of plunging into a bear market, few Wall Street experts were predicting that the ...

Following a pre-Congress press briefing and data presented onsite at ASCO 2025 itself, pharmaphorum spoke with Dr Victoria ...

This newsletter is taking a summer break next week but will return to your inbox the following Monday. Enjoy your July 4 ...

Merck KGaA executive Renee Connolly and Gen Z recording artist Lola Young joined Havas Health and Creative Networks CEO Donna ...

Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

AI has been a buzzword in the pharmaceutical industry for almost a decade, with countless headlines promising to ...